Commentary

TikTok’s fave weight loss drugs: Link to thyroid cancer?


 

How to advise our patients and respond to the EMR messages

The TikTok videos may continue, the celebrity chatter may increase, and we, as physicians, will continue to look to real-world data with randomized controlled trials to tailor our decision-making and guide our patients.

It’s prudent to advise patients that if they have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, in particular, they should avoid using this class of medication. Thyroid cancer remains a rare outcome, and GLP-1 receptor agonists remain a very important and beneficial treatment option for the right patient.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Don’t be afraid of weight gain with hyperthyroid treatment
MDedge Internal Medicine
Stopping levothyroxine in subclinical hypothyroidism safe, feasible
MDedge Internal Medicine
USPSTF holds firm on postmenopausal hormone recommendations
MDedge Internal Medicine
Thyroid nodule volume reduction correlates with energy in ablation
MDedge Internal Medicine
‘Game changer’: Thyroid cancer recurrence no higher with lobectomy
MDedge Internal Medicine
Lifestyle choices could curb genetic risk for thyroid cancer
MDedge Internal Medicine
New consensus on thyroid eye disease prompts some debate
MDedge Internal Medicine
Commenting on weight’s not rude. It’s dangerous.
MDedge Internal Medicine
What do high BUN/Cr ratios mean?
MDedge Internal Medicine
What’s it like to take Ozempic? A doctor’s own story
MDedge Internal Medicine